Show simple item record

dc.contributor.authorPurcell, Anna Lydia
dc.contributor.authorHeard, Henry
dc.date.accessioned2021-04-06T20:16:55Z
dc.date.available2021-04-06T20:16:55Z
dc.date.issued2021
dc.identifier.urihttp://hdl.handle.net/10898/12534
dc.description.abstractHepatitis C is an RNA virus that affects millions in the United States and globally, but with recent pharmacological achievements, the cure rate of hepatitis C has increased greatly. Hepatitis C is transmitted by blood, with the main infections in the US being cause by IV drug use and blood transfusions prior to 1992. Hepatitis C has six genotypes, but the overwhelming majority of cases in America are genotypes 1, 2, and 3. Diagnosis of hepatitis C is difficult due to the lack of symptoms on presentation. Screening in high risk populations has shown to be efficacious in diagnosing the disease. Previous treatment norms consisted of interferon, but cure rates were very low. In 2011, direct-acting antivirals were introduced and revolutionized the treatment of hepatitis C. Response rates have increased exponentially to over 95%, and the medications are much more tolerable.
dc.subjectCollege of Health Professions
dc.subjectARC21--Night 3
dc.titleCurrent Treatment for Hepatitis C Patients: A Review
dc.typePresentation
refterms.dateFOA2021-04-06T20:16:55Z


Files in this item

Thumbnail
Name:
ARC21_COHP_010.pdf
Size:
417.8Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record